Navigation Links
Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st
Date:11/29/2011

NEW YORK, Nov. 29, 2011 /PRNewswire/ -- Senesco Technologies, Inc. (NYSE AMEX: SNT) announced that that Leslie J. Browne, Ph.D., President and CEO, will present at RetailInvestorConferences.com.

DATE: December 1, 2011
TIME: 10:00 AM EST
LINK: www.retailinvestorconferences.com > Click the red "register/ watch event now" button.

This will be a live, interactive online event where investors are invited to ask the company questions in real-time both in the presentation hall as well as the company's "virtual trade booth." If attendees are not able to join the event live in real-time, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register to save time and receive event updates.

Senesco recently initiated patient dosing at the Mayo Clinic in Rochester, MN, in a Phase 1b/2a clinical study of SNS01-T, the Company's lead therapeutic candidate for the treatment of multiple myeloma, and also indicated its plan to initiate in 2012 an additional clinical study of SNS01-T in other B-cell cancers. The Company has demonstrated in the laboratory that SNS01-T can significantly inhibit the growth of both human mantle cell and diffuse large B-cell lymphomas in a dose dependent manner in mouse xenograft models. Potential additional effectiveness was observed from in vitro studies in which SNS01-T was combined with other approved myeloma drugs. "We believe we have shown that certain myeloma drugs can be up to 40 times more potent in vitro when used in combination with SNS01-T," stated Leslie J. Browne, Ph.D., President and CEO of Senesco. "Together these results further reinforce the significance of our target, eIF5A, and will guide us in designing our future clinical studies."

About Multiple Myeloma

Multiple myeloma is an incurable cancer of plasma cells, a type of white blood cell derived from B-lymphocytes, normally responsible for the production of antibodies. Malignant plasma cells accumulate in the bone marrow leading to bone lesions and interfering with the production of normal white blood cells. Median survival time from first treatment is 2½ to 5 years depending on disease stage at diagnosis. In the United States there are approximately 20,000 newly diagnosed cases of multiple myeloma annually and a total of approximately 65,000 patients with the disease. Senesco was previously granted orphan drug status for SNS01-T, the Company's lead drug candidate for treatment of multiple myeloma.

About Senesco Technologies, Inc.

Senesco Technologies is leveraging proprietary technology that regulates programmed cell death, or apoptosis. Accelerating apoptosis may have applications in treating cancer, while delaying apoptosis may have applications treating certain inflammatory and ischemic diseases. The Company has initiated a clinical study in multiple myeloma with its lead therapeutic candidate SNS01-T. Senesco has already partnered with leading-edge companies engaged in agricultural biotechnology, and is entitled to earn research and development milestones and royalties if its gene-regulating platform technology is incorporated into its partners' products.

Forward-Looking Statements

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate additional financings; the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's products; the timing and success of the Company's preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance, the Company's ability to comply with the continued listing standards of the NYSE Amex, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

About RetailInvestorConferences.com:

RetailInvestorConferences.com, created by BetterInvesting (NAIC), PR Newswire and MUNCmedia, is the first monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.

 


'/>"/>
SOURCE Senesco Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
2. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
3. Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring
4. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
5. Senesco Technologies Reports Third Quarter Fiscal 2009 Financial Results
6. Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy
7. Senesco Technologies, Inc. Announces the Appointment of Dr. Harlan W. Waksal, M.D. as Chairman of the Board of Directors and the Addition of Mr. Warren J. Isabelle, CFA to its Board of Directors
8. ArborGen and Senesco Announce Wood Quality Results
9. Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing
10. Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing
11. Senesco Technologies to Present at 11th Annual Rodman & Renshaw Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2018)... (PRWEB) , ... August 29, 2018 , ... ... Professorships at both the University of Southampton and the Institute of Industrial Science, ... intelligence at sea can dramatically accelerate the exploration and study of hard to ...
(Date:8/29/2018)... ... 28, 2018 , ... CEO and founder of VetStem Biopharma, ... on an allogeneic (donor derived) stem cell product for osteoarthritis in canines at ... September. He is also the organizer of Breakout Session 4: Practitioner Primer on ...
(Date:8/23/2018)... Nev. (PRWEB) , ... August 22, 2018 , ... ... TrialKit ™ for Android on September 1st, making it the first fully-featured app ... iOS and Android devices. Combined, iOS and Android constitute 99 percent of the ...
(Date:8/17/2018)... ... August 16, 2018 , ... KCAS ... to announce the expansion of their team. Dr. Dawn Dufield, Ph.D., joins KCAS ... innovative large molecule LC-MS/MS group that will specialize in developing quantitative LC-MS/MS assays ...
Breaking Biology Technology:
(Date:9/22/2018)... ... 21, 2018 , ... VTE can present as deep vein ... significant morbidity and mortality. VTE affects between 300-600,000 Americans annually, with approximately 100,000 ... the leading cause of preventable hospital death and maternal mortality. When used with ...
(Date:9/12/2018)... ... September 10, 2018 , ... IONpathTM, a venture-backed commercial-stage ... Multiplexed Ion Beam Imaging (MIBITM) technology was accepted by the journal Cell and ... shared during a webinar presented by Dr. Mike Angelo on October 2nd, 2018. ...
(Date:9/12/2018)... , ... September 12, 2018 , ... ... spine fusion solutions announced today it has received 510(k) clearance from the U.S. ... complementing its TowerLOX® MIS Pedicle Screw System. , TowerLOX-EXT MIS Extended Tab Pedicle ...
Breaking Biology News(10 mins):